The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations
Open accessAbstract
Glucocerebrosidase (GBA) mutations have been associated with Parkinson's disease in numerous studies. However, it is unknown whether the increased risk of Parkinson's disease in GBA carriers is due to a loss of glucocerebrosidase enzymatic activity. We measured glucocerebrosidase enzymatic activity in dried blood spots in patients with Parkinson's disease (n = 517) and controls (n = 252) with and without GBA mutations. Participants were recruited from Columbia University, New York, and fully sequenced for GBA mutations and genotyped for the LRRK2 G2019S mutation, the most common autosomal dominant mutation in the Ashkenazi Jewish population. Glucocerebrosidase enzymatic activity in dried blood spots was measured by a mass spectrometry-based assay and compared among participants categorized by GBA mutation status and Parkinson's disease diagnosis. Parkinson's disease patients were more likely than controls to carry the LRRK2 G2019S mutation (n = 39, 7.5% versus n = 2, 0.8%, P < 0.001) and GBA mutations or variants (seven homozygotes and compound heterozygotes and 81 heterozygotes, 17.0% versus 17 heterozygotes, 6.7%, P < 0.001). GBA homozygotes/compound heterozygotes had lower enzymatic activity than GBA heterozygotes (0.85 µmol/l/h versus 7.88 µmol/l/h, P < 0.001), and GBA heterozygotes had lower enzymatic activity than GBA and LRRK2 non-carriers (7.88 µmol/l/h versus 11.93 µmol/l/h, P < 0.001). Glucocerebrosidase activity was reduced in heterozygotes compared to non-carriers when each mutation was compared independently (N370S, P < 0.001; L444P, P < 0.001; 84GG, P = 0.003; R496H, P = 0.018) and also reduced in GBA variants associated with Parkinson's risk but not with Gaucher disease (E326K, P = 0.009; T369M, P < 0.001). When all patients with Parkinson's disease were considered, they had lower mean glucocerebrosidase enzymatic activity than controls (11.14 µmol/l/h versus 11.85 µmol/l/h, P = 0.011). Difference compared to controls persisted in patients with idiopathic Parkinson's disease (after exclusion of all GBA and LRRK2 carriers; 11.53 µmol/l/h, versus 12.11 µmol/l/h, P = 0.036) and after adjustment for age and gender (P = 0.012). Interestingly, LRRK2 G2019S carriers (n = 36), most of whom had Parkinson's disease, had higher enzymatic activity than non-carriers (13.69 µmol/l/h versus 11.93 µmol/l/h, P = 0.002). In patients with idiopathic Parkinson's, higher glucocerebrosidase enzymatic activity was associated with longer disease duration (P = 0.002) in adjusted models, suggesting a milder disease course. We conclude that lower glucocerebrosidase enzymatic activity is strongly associated with GBA mutations, and modestly with idiopathic Parkinson's disease. The association of lower glucocerebrosidase activity in both GBA mutation carriers and Parkinson's patients without GBA mutations suggests that loss of glucocerebrosidase function contributes to the pathogenesis of Parkinson's disease. High glucocerebrosidase enzymatic activity in LRRK2 G2019S carriers may reflect a distinct pathogenic mechanism. Taken together, these data suggest that glucocerebrosidase enzymatic activity could be a modifiable therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553 · cited 8×
“In regression models, only age, disease duration and Montreal Cognitive Assessment performance were associated with high glucocerebrosidase enzymatic activity.”
MethodInfluentialHughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Self-citationMulticenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationMazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696
Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Interplay of LRRK2 with chaperone-mediated autophagy
Orenstein, S. J., Kuo, S.-H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I., Cortes, E., Honig, L. S., Dauer, W., Consiglio, A., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3350 · Cited by 588 · cited 1×
“One possible explanation is that mutant LRRK2 may cause lysosomal compartment expansion (Orenstein et al ., 2013), which in turn is associated with increased glucocerebrosidase enzymatic activity.”
BackgroundSelf-citationThe link between the GBA gene and parkinsonism
Sidransky, E., & Lopez, G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70190-4 · Cited by 583
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains
Gegg, M. E., Burke, D., Heales, S. J. R., Cooper, J. M., Hardy, J., Wood, N. W., & Schapira, A. H. V. (2012) · Annals of Neurology · doi:10.1002/ana.23614 · Cited by 564
RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson’s Disease Risk
MacLeod, D. A., Rhinn, H., Kuwahara, T., Zolin, A., Di Paolo, G., McCabe, B. D., Marder, K. S., Honig, L. S., Clark, L. N., Small, S. A., et al. (2013) · Neuron · doi:10.1016/j.neuron.2012.11.033 · Cited by 516
Self-citationReduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M. (2014) · Brain · doi:10.1093/brain/awt367 · Cited by 475 · cited 2×
“…enzymatic activity has been previously reported in Parkinson’s disease and Lewy body dementia in CSF (Balducci et al ., 2007; Parnetti et al ., 2009, 2014) and in two brain autopsy studies (Gegg et al ., 2012; Murphy et al ., 2014), findings which are consistent with our observation.”
ResultOccurrence of Parkinson's syndrome in type 1 Gaucher disease
Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., & Zimran, A. (1996) · QJM · doi:10.1093/qjmed/89.9.691 · Cited by 401
Glucocerebrosidase mutations in subjects with parkinsonism
Lwin, A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.11.004 · Cited by 371
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset
Gan-Or, Z., Giladi, N., Rozovski, U., Shifrin, C., Rosner, S., Gurevich, T., Bar-Shira, A., & Orr-Urtreger, A. (2008) · Neurology · doi:10.1212/01.wnl.0000304039.11891.29 · Cited by 360
Self-citationMcNeill, A., Magalhaes, J., Shen, C., Chau, K.-Y., Hughes, D., Mehta, A., Foltynie, T., Cooper, J. M., Abramov, A. Y., Gegg, M., et al. (2014) · Brain · doi:10.1093/brain/awu020 · Cited by 321
Sardi, S. P., Clarke, J., Kinnecom, C., Tamsett, T. J., Li, L., Stanek, L. M., Passini, M. A., Grabowski, G. A., Schlossmacher, M. G., Sidman, R. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108197108 · Cited by 319
Cullen, V., Sardi, S. P., Ng, J., Xu, Y., Sun, Y., Tomlinson, J. J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22400 · Cited by 303
Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease
Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., Dardis, A., Deganuto, M., De Carlo, C., Castrioto, A., et al. (2014) · Movement Disorders · doi:10.1002/mds.25772 · Cited by 266
Cognitive performance of GBA mutation carriers with early-onset PD: The CORE-PD study
Alcalay, R. N., Caccappolo, E., Mejia-Santana, H., Tang, M.-X., Rosado, L., Orbe Reilly, M., Ruiz, D., Ross, B., Verbitsky, M., Kisselev, S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318253d54b · Cited by 262
Self-citationMUTATIONS IN GBA ARE ASSOCIATED WITH FAMILIAL PARKINSON DISEASE SUSCEPTIBILITY AND AGE AT ONSET
Sidransky, E., Samaddar, T., & Tayebi, N. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b28601 · Cited by 259
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease
Clark, L. N., Ross, B. M., Wang, Y., Mejia-Santana, H., Harris, J., Louis, E. D., Cote, L. J., Andrews, H., Fahn, S., Waters, C., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000276989.17578.02 · Cited by 252
Self-citationWoodard, C. M., Campos, B. A., Kuo, S.-H., Nirenberg, M. J., Nestor, M. W., Zimmer, M., Mosharov, E. V., Sulzer, D., Zhou, H., Paull, D., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.023 · Cited by 222
Self-citationComparison of Parkinson Risk in Ashkenazi Jewish Patients With Gaucher Disease and GBA Heterozygotes
Alcalay, R. N., Dinur, T., Quinn, T., Sakanaka, K., Levy, O., Waters, C., Fahn, S., Dorovski, T., Chung, W. K., Pauciulo, M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.313 · Cited by 217
Self-citationMutations for Gaucher Disease Confer High Susceptibility to Parkinson Disease
Mitsui, J., Mizuta, I., Toyoda, A., Ashida, R., Takahashi, Y., Goto, J., Fukuda, Y., Date, H., Iwata, A., Yamamoto, M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.72 · Cited by 209
Association of Glucocerebrosidase Mutations With Dementia With Lewy Bodies
Clark, L. N., Kartsaklis, L. A., Wolf Gilbert, R., Dorado, B., Ross, B. M., Kisselev, S., Verbitsky, M., Mejia-Santana, H., Cote, L. J., Andrews, H., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.54 · Cited by 202
Self-citationMutations in GBA are associated with familial Parkinson disease susceptibility and age at onset
Nichols, W. C., Pankratz, N., Marek, D. K., Pauciulo, M. W., Elsaesser, V. E., Halter, C. A., Rudolph, A., Wojcieszek, J., Pfeiffer, R. F., & Foroud, T. (2009) · Neurology · doi:10.1212/01.wnl.0000327823.81237.d1 · Cited by 202
Self-citationThe Spectrum of Parkinsonian Manifestations Associated With Glucocerebrosidase Mutations
Goker-Alpan, O., Lopez, G., Vithayathil, J., Davis, J., Hallett, M., & Sidransky, E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.10.1353 · Cited by 199
Zhang, X. K., Elbin, C. S., Chuang, W.-L., Cooper, S. K., Marashio, C. A., Beauregard, C., & Keutzer, J. M. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.104711 · Cited by 176
Self-citationRosenbloom, B., Balwani, M., Bronstein, J. M., Kolodny, E., Sathe, S., Gwosdow, A. R., Taylor, J. S., Cole, J. A., Zimran, A., & Weinreb, N. J. (2011) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2010.10.006 · Cited by 158
Durán, R., Mencacci, N. E., Angeli, A., Shoai, M., Deas, E., Houlden, H., Mehta, A. B., Hughes, D. A., Cox, T. M., Deegan, P. B., et al. (2012) · Movement Disorders · doi:10.1002/mds.25248 · Cited by 147
Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations
Alcalay, R. N., Mirelman, A., Saunders-Pullman, R. J., Tang, M., Santana, H. M., Raymond, D., Roos, E., Orbe‐Reilly, M., Gurevich, T., Shira, A. B., et al. (2013) · Movement Disorders · doi:10.1002/mds.25647 · Cited by 139
Self-citationIncreased incidence of Parkinson disease among relatives of patients with Gaucher disease
Halperin, A., Elstein, D., & Zimran, A. (2006) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2006.02.004 · Cited by 138
Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease.
Raghavan, S. S., Topol, J., & Kolodny, E. H. (1980) · Europe PMC (PubMed Central) · Cited by 125
Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease
Balducci, C., Pierguidi, L., Persichetti, E., Parnetti, L., Sbaragli, M., Tassi, C., Orlacchio, A., Calabresi, P., Beccari, T., & Rossi, A. (2007) · Movement Disorders · doi:10.1002/mds.21399 · Cited by 121
Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal
Brás, J., Paisán‐Ruiz, C., Guerreiro, R. J., Ribeiro, M. H., Morgadinho, A., Januário, C., Sidransky, E., Oliveira, C. R., & Singleton, A. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.016 · Cited by 117
Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population
Horowitz, M., Pasmanik‐Chor, M., Borochowitz, Z. U., Zaccai, T. C. F., Heldmann, K., Carmi, R., Parvari, R., Beit-Or, H., Goldman, B., Peleg, L., et al. (1998) · Human Mutation · Cited by 99
Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece
Kalinderi, K., Bostantjopoulou, S., Paisán‐Ruiz, C., Katsarou, Z., Hardy, J., & Fidani, L. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.01.029 · Cited by 94
Automated Identification of Single Nucleotide Polymorphisms from Sequencing Data
Takahashi, M., Matsuda, F., Margetic, N., & Lathrop, M. G. (2003) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s021972000300006x · Cited by 93
Reuser, A. J. J., Verheijen, F. W., Bali, D. S., van Diggelen, O. P., Germain, D. P., Hwu, W., Lukács, Z., Mühl, A., Olivova, P., Piraud, M., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.07.014 · Cited by 82
Self-citationA mutation in SCARB2 is a modifier in gaucher disease
Velayati, A., DePaolo, J., Gupta, N., Choi, J. H., Moaven, N., Westbroek, W., Göker-Alpan, Ö., Goldin, E., Stubblefield, B. K., Kolodny, E. H., et al. (2011) · Human Mutation · doi:10.1002/humu.21566 · Cited by 81
Accuracy of family history data on Parkinson’s disease
Marder, K. S., Levy, G., Louis, E. D., Mejia‐Santana, H., Cote, L. J., Andrews, H., Harris, J. M., Waters, C., Ford, B., Frucht, S. J., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000074784.35961.c0 · Cited by 77
Self-citationCerebrospinal fluid β-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies
Parnetti, L., Balducci, C., Pierguidi, L., Carlo, C. D., Peducci, M., D’Amore, C., Padiglioni, C., Mastrocola, S., Persichetti, E., Paciotti, S., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.03.002 · Cited by 71
The enigma of the E326K mutation in acid β-glucocerebrosidase
Horowitz, M., Pasmanik‐Chor, M., Ron, I., & Kolodny, E. H. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.07.002 · Cited by 54
An improved high-throughput dried blood spot screening method for Gaucher disease
Olivova, P., Cullen, E., Titlow, M., Kallwass, H. K. W., Barranger, J. A., Zhang, K., & Keutzer, J. M. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.08.024 · Cited by 40
Self-citationKnowledge of and Interest in Genetic Results Among Parkinson Disease Patients and Caregivers
Sakanaka, K., Waters, C., Levy, O. A., Louis, E. D., Chung, W. K., Marder, K. S., & Alcalay, R. N. (2013) · Journal of Genetic Counseling · doi:10.1007/s10897-013-9618-y · Cited by 35
Self-citationGrabowski, G. A., Dinur, T., Gátt, S., & Desnick, R. J. (1982) · Clinica Chimica Acta · doi:10.1016/0009-8981(82)90326-6 · Cited by 34
Salvioli, R., Tatti, M., Ciaffoni, F., & Vaccaro, A. M. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01417-4 · Cited by 31
Giraldo, P., Capablo, J. L., Alfonso, P., Garcia‐Rodriguez, B., Latre, P., Irún, P., de Cabezón, A. S., & Pocoví, M. (2011) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9298-4 · Cited by 20
Cited by
T cells from patients with Parkinson’s disease recognize α-synuclein peptides
Sulzer, D., Alcalay, R. N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., Liong, C., McMurtrey, C., Hildebrand, W. H., Mao, X., et al. (2017) · Nature · doi:10.1038/nature22815 · Cited by 866
Self-citationParkinson disease and the immune system - Associations, mechanisms and therapeutics
Tan, E.-K., Chao, Y.-X., West, A., Chan, L.-L., Poewe, W., & Jankovic, J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0344-4 · Cited by 457
Genetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance
Hernandez, D. G., Reed, X., & Singleton, A. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13593 · Cited by 448
Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease
Robak, L. A., Jansen, I. E., van Rooij, J., Uitterlinden, A. G., Kraaij, R., Jankovic, J., Heutink, P., Shulman, J. M., International Parkinson’s Disease Genomics Consortium (IPDGC), Nalls, M. A., et al. (2017) · Brain · doi:10.1093/brain/awx285 · Cited by 433
Progress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
Metadata
- Authors
- Alcalay, R. N., Levy, O. A., Waters, C. H., Fahn, S., Ford, B., Kuo, S.-H., Mazzoni, P., Pauciulo, M. W., Nichols, W. C., Gan-Or, Z., Rouleau, G. A., Chung, W. K., Wolf, P., Oliva, P., Keutzer, J., Marder, K., & Zhang, X.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-06-27
- Volume
- 138
- Issue
- 9
- Pages
- 2648-2658
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2136230100
- Cited by
- 392
- References
- 49
- FWCI
- 18.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.